Download PDF
Am J Perinatol
DOI: 10.1055/a-2257-3586
Original Article

Oral versus intravenous iron for anemia in pregnancy: a cost-effectiveness analysis

Wayde D.H. Dazelle 
,
Megan K Ebner
1   The George Washington University School of Medicine and Health Sciences, Washington, United States (Ringgold ID: RIN43989)
,
Savita Potarazu
1   The George Washington University School of Medicine and Health Sciences, Washington, United States (Ringgold ID: RIN43989)
,
Jamil Kazma
2   George Washington University Hosptial, Washington DC, United States
,
Homa Ahmadzia
3   OB/Gyn, George Washington University Medical Faculty Associates, Washington, United States (Ringgold ID: RIN50515)
› Author Affiliations
› Further Information
Also available at
  PDF Download

Our findings suggest that treating antepartum anemia with currently available iron therapies would result in significant cost-savings and reductions in adverse outcomes associated with anemia in this context. Ferric carboxymaltose likely confers the greatest overall benefit among competing options. This conclusion is robust to uncertainty, even when the cost these therapies is significantly higher than is demonstrated in the literature.



Publication History

Received: 10 January 2023

Accepted after revision: 28 January 2024

Accepted Manuscript online:
30 January 2024

© . Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor , NY 10001 New York, USA